Product
STRO-002
3 clinical trials
6 indications
Indication
Malignant NeoplasmsIndication
Ovarian CancerIndication
Endometrial CancerIndication
Endometrioid AdenocarcinomaIndication
Fallopian tube cancerIndication
Primary Peritoneal CarcinomaClinical trial
A Phase I/IIa Study to Evaluate the Safety, Tolerability , Pharmacokinetics and Preliminary Efficacy of STRO-002 in Chinese Adults With Advanced Epithelial Ovarian Cancer, Endometrial Cancer, and Other Advanced Malignant Solid Tumors.Status: Recruiting, Estimated PCD: 2026-12-30
Clinical trial
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial CancersStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)Status: Active (not recruiting), Estimated PCD: 2025-12-01